EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-11
DOI
10.1038/s41388-021-01721-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
- (2019) Rachael A. Vaubel et al. CLINICAL CANCER RESEARCH
- EGFRvIII: An Oncogene with Ambiguous Role
- (2019) Adrianna Rutkowska et al. Journal of Oncology
- Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma
- (2018) Ana C. deCarvalho et al. NATURE GENETICS
- The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation
- (2018) Wojciech Stec et al. Oncotarget
- A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine
- (2018) Hyun Jung Jun et al. Nature Communications
- A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
- (2018) Alison M. Schram et al. BRITISH JOURNAL OF CANCER
- The RTK Interactome: Overview and Perspective on RTK Heterointeractions
- (2018) Michael D. Paul et al. CHEMICAL REVIEWS
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity
- (2017) Kristen M. Turner et al. NATURE
- Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma
- (2017) Robert S McNeill et al. NEURO-ONCOLOGY
- A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
- (2017) Zev A. Wainberg et al. Targeted Oncology
- Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma
- (2017) Spyros Darmanis et al. Cell Reports
- EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines
- (2017) Debyani Chakravarty et al. Scientific Reports
- A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
- (2016) J. E. Grilley-Olson et al. INVESTIGATIONAL NEW DRUGS
- Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
- (2016) Saya H. Ebbesen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PTEN regulates lung endodermal morphogenesis through MEK/ERK pathway
- (2015) Yiming Xing et al. DEVELOPMENTAL BIOLOGY
- EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications
- (2015) S A Greenall et al. ONCOGENE
- Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity
- (2015) Mona Meyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited
- (2015) Nicola Montano et al. NEOPLASIA
- Regulation of HGF Expression by ΔEGFR-Mediated c-Met Activation in Glioblastoma Cells
- (2015) Jeannine Garnett et al. NEOPLASIA
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
- (2014) M. A. Lemmon et al. Cold Spring Harbor Perspectives in Biology
- EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
- (2014) J. M. Francis et al. Cancer Discovery
- Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
- (2013) Edward R. Kastenhuber et al. ACTA NEUROPATHOLOGICA
- EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma
- (2013) Qi-Wen Fan et al. CANCER CELL
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation
- (2013) Rama Kancha et al. Cell Communication and Signaling
- The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
- (2013) Hui K. Gan et al. FEBS Journal
- Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
- (2013) David A. Nathanson et al. SCIENCE
- Platelet-derived growth factors and their receptors: Structural and functional perspectives
- (2012) Po-Han Chen et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- In Situ Analysis of Mutant EGFRs Prevalent in Glioblastoma Multiforme Reveals Aberrant Dimerization, Activation, and Differential Response to Anti-EGFR Targeted Therapy
- (2012) A. S. Gajadhar et al. MOLECULAR CANCER RESEARCH
- Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
- (2012) N. J. Szerlip et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
- (2011) Matija Snuderl et al. CANCER CELL
- Forced Dimerization Increases the Activity of EGFR/EGFRvIII and Enhances Its Oncogenicity
- (2011) Y. Hwang et al. MOLECULAR CANCER RESEARCH
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation
- (2011) Susie I. Ymer et al. Cancers
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
- (2009) Michael Weller et al. JOURNAL OF CLINICAL ONCOLOGY
- A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
- (2009) Linda Madisen et al. NATURE NEUROSCIENCE
- Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis
- (2009) Haihao Zhu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search